Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

An2 Therapeutics Inc (ANTX)

An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Insider Purchase: Director at $ANTX (ANTX) Buys 5,000 Shares

Joseph S Zakrzewski, a director at $ANTX ($ANTX), bought 5,000 shares of the company on 11-19-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...

ANTX : 1.2300 (-5.38%)
The Five Biotech Stocks Every Investor Should Know About

Avalon GloboCare Corp., (NASDAQ: ALBT) a developer of innovative precision diagnostics and provider of clinical laboratory services just announced that the United States Patent and Trademark Office (USPTO)...

ALBT : 2.65 (-4.68%)
INSM : 73.81 (+1.57%)
VIR : 6.95 (+3.12%)
CODX : 1.0600 (+1.92%)
ANTX : 1.2300 (-5.38%)
A Potentially Revolutionary Tuberculosis Test Can Produce Results in 24 Hours

With a rising prevalence of chronic diseases, we’re starting to see higher demand for clinical lab services. That being said, it’s no surprise that, according to Market.Us, the global market for clinical...

INSM : 73.81 (+1.57%)
VIR : 6.95 (+3.12%)
CODX : 1.0600 (+1.92%)
ANTX : 1.2300 (-5.38%)
ALBT : 2.65 (-4.68%)
Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from...

VIR : 6.95 (+3.12%)
VBIV : 0.0653 (-50.87%)
ANTX : 1.2300 (-5.38%)
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 1.2300 (-5.38%)
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported...

ANTX : 1.2300 (-5.38%)
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 6.95 (+3.12%)
VBIV : 0.0653 (-50.87%)
ANTX : 1.2300 (-5.38%)
AN2 Therapeutics to Participate in Upcoming Investor Conferences

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 1.2300 (-5.38%)
AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced...

ANTX : 1.2300 (-5.38%)
AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease

AN2 is developing epetraborole as a once-daily, orally administered treatment with a novel mechanism of action for patients with NTM lung disease, with an...

ANTX : 1.2300 (-5.38%)

Barchart Exclusives

Enerflex Means Drill Baby Drill
Summary Enerflex Ltd. (EFXT) shows strong technical buy signals, with a 59.86% gain since 9/19 and a 117.92% gain in the last year. The company provides comprehensive energy infrastructure solutions, including natural gas compression, power generation, and low-carbon solutions, with a market cap of $1.12 billion. Analysts give mixed ratings,... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar